DROXIA Drug Patent Profile

Which patents cover Droxia, and what generic alternatives are available?

Droxia is a drug marketed by Waylis Therap and is included in one NDA.

The generic ingredient in DROXIA is hydroxyurea. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the hydroxyurea profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Droxia

A generic version of DROXIA was approved as hydroxyurea by BARR on October 16^th, 1998.

Summary for DROXIA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DROXIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	DROXIA	hydroxyurea	CAPSULE;ORAL	016295-002	Feb 25, 1998		DISCN	Yes	No
Waylis Therap	DROXIA	hydroxyurea	CAPSULE;ORAL	016295-003	Feb 25, 1998		DISCN	Yes	No
Waylis Therap	DROXIA	hydroxyurea	CAPSULE;ORAL	016295-004	Feb 25, 1998		DISCN	Yes	No

Droxia (Hydroxyurea) Investment and Fundamentals Analysis

Last updated: February 19, 2026

Droxia (hydroxyurea) is an antineoplastic agent used in the treatment of sickle cell anemia and certain myeloproliferative neoplasms. This analysis examines the drug's market position, patent landscape, and future prospects to inform investment decisions.

What is the Market Landscape for Droxia?

Droxia's primary indications are sickle cell disease (SCD) and specific myeloproliferative neoplasms (MPNs). The SCD market is characterized by a significant unmet need and increasing recognition, while the MPN market is more established and competitive.

Sickle Cell Disease Market

Sickle cell disease is a group of inherited red blood cell disorders. In the U.S., it affects an estimated 100,000 people, with an annual incidence of approximately 2,000 new cases [1]. Globally, SCD is a major public health issue, particularly in sub-Saharan Africa, India, and the Middle East.

Historically, SCD management has focused on supportive care, including pain management, blood transfusions, and infection prophylaxis. Hydroxyurea, first approved by the FDA for SCD in 1998 under the brand name Droxia, was a breakthrough therapy. It works by increasing fetal hemoglobin (HbF) levels, which reduces sickling of red blood cells, leading to fewer vaso-occlusive crises, hospitalizations, and transfusions [2].

The U.S. market for SCD treatments is expanding due to increased disease awareness, improved diagnostic capabilities, and the development of novel therapies. Beyond hydroxyurea, approved treatments include L-glutamine (Endari), crizanlizumab (Adakveo), and voxelotor (Oxbryta). Emerging therapies in development target various SCD pathologies, including gene therapies and gene editing [3].

The economic burden of SCD is substantial, encompassing direct medical costs and indirect costs associated with lost productivity. In the U.S., annual costs for SCD care are estimated to be between $2.5 billion and $3 billion [4].

Myeloproliferative Neoplasms Market

Droxia is also indicated for the treatment of certain myeloproliferative neoplasms (MPNs), including chronic myeloid leukemia (CML) and polycythemia vera (PV). In these conditions, Droxia helps to reduce the number of abnormal white blood cells and platelets.

The global MPN market is projected to grow, driven by an aging population, increased diagnosis rates, and the availability of targeted therapies. Key MPN indications for hydroxyurea include:

• Polycythemia Vera (PV): A condition characterized by the overproduction of red blood cells.
• Essential Thrombocythemia (ET): A disorder where the bone marrow produces too many platelets.
• Myelofibrosis (MF): A serious bone marrow disorder.

The competitive landscape for MPNs includes other agents like interferon alfa, anagrelide, and ruxolitinib (Jakafi), a Janus kinase (JAK) inhibitor that has significantly impacted the treatment of myelofibrosis [5]. The market for PV and ET is more mature, with hydroxyurea remaining a cornerstone therapy for many patients, particularly those with lower-risk disease.

What is the Patent and Regulatory Status of Droxia?

Understanding the patent and regulatory landscape is crucial for assessing Droxia's market exclusivity and potential for generic competition.

Original Patent Expiration and Generic Entry

Droxia (hydroxyurea) was originally approved by the U.S. Food and Drug Administration (FDA) in 1998. The compound itself is a well-established molecule with its patent protection having long expired. This has paved the way for multiple generic manufacturers to enter the market.

Key dates and events:

• Original Approval (U.S.): 1998
• Compound Patent Expiration: Pre-2000s (well expired)
• Generic Approvals: Numerous generic versions of hydroxyurea have been approved by the FDA since the early 2000s.

The presence of multiple generic manufacturers has led to significant price erosion for hydroxyurea. The cost of generic hydroxyurea is substantially lower than the original branded product. This impacts revenue for any entity holding rights to the branded product or its specific formulations.

Formulation and Indication Patents

While the core compound patent has expired, there can be secondary patents related to specific formulations, manufacturing processes, or new indications. However, for Droxia, these secondary patents have also largely expired or have not provided sustained market exclusivity.

• Formulation Patents: Patents covering specific drug delivery systems or excipients for hydroxyurea have been pursued, but their impact on broad market exclusivity has been limited due to the established generic presence.
• Indication Expansion Patents: Patents related to the use of hydroxyurea for specific patient populations or treatment regimens within SCD or MPNs may exist. However, regulatory exclusivities granted for new indications are separate from patent protection.

Regulatory Exclusivities

The FDA can grant market exclusivities for certain periods. For Droxia, key exclusivities include:

• New Chemical Entity (NCE) Exclusivity: Not applicable, as hydroxyurea was an established compound.
• New Indication Exclusivity: When hydroxyurea was approved for SCD, it received regulatory exclusivity for that specific use. However, this exclusivity period has long concluded, and generic manufacturers can market hydroxyurea for approved indications.
• Orphan Drug Exclusivity: For rare diseases, like SCD, orphan drug exclusivity can be granted. Hydroxyurea received Orphan Drug Designation for sickle cell disease, granting 7 years of market exclusivity from the date of approval for that indication. This exclusivity period would have expired by the late 2000s.

Current Market Dynamics

The current market for hydroxyurea is predominantly generic. Brand-name Droxia exists but faces intense competition from a multitude of generic equivalents. This market structure limits the pricing power and revenue potential for the branded product. Investment in the branded Droxia product itself would be subject to significant price pressure and market share erosion from generics. However, for companies involved in generic manufacturing or supplying active pharmaceutical ingredients (APIs), the demand remains stable due to the drug's established efficacy and affordability.

What are the Clinical Data and Efficacy of Droxia?

Droxia's efficacy is well-documented, particularly in sickle cell disease, where it has been a standard of care for decades.

Efficacy in Sickle Cell Disease

Clinical trials have consistently demonstrated hydroxyurea's benefits in reducing the morbidity and mortality associated with SCD.

Key Clinical Trial Findings:

• Reduction in Vaso-occlusive Crises (VOCs): The landmark Multicenter Study of Hydroxyurea in Sickle Cell Disease (MSHCSD) showed a significant reduction in painful crises requiring hospitalization. Patients treated with hydroxyurea experienced approximately 30% fewer VOCs annually compared to placebo [6].
• Decreased Hospitalizations: Hospital admissions for SCD-related complications, including VOCs and acute chest syndrome, were reduced by an average of 30-50% in patients on hydroxyurea [2, 6].
• Increased Fetal Hemoglobin (HbF): Hydroxyurea is a potent inducer of HbF. Increased HbF levels interfere with hemoglobin S polymerization, thereby mitigating red blood cell sickling. MSHCSD reported an average increase in HbF from around 2% to over 20% [6].
• Reduced Need for Blood Transfusions: Studies show a decrease in the frequency of blood transfusions required by SCD patients treated with hydroxyurea [2].
• Improved Quality of Life: While objective measures like VOCs are primary endpoints, patient-reported outcomes often reflect improvements in pain, fatigue, and overall well-being.

Long-term Data:

Long-term follow-up studies, such as the extension phase of the MSHCSD, have continued to show sustained benefits and an improved survival rate in patients treated with hydroxyurea compared to historical controls [7].

Efficacy in Myeloproliferative Neoplasms

Droxia is also established in treating certain MPNs.

• Polycythemia Vera (PV): Hydroxyurea is used to control elevated red blood cell counts and platelet counts, reducing the risk of thrombotic events. Efficacy is measured by achieving and maintaining target hematocrit levels and reducing platelet counts to acceptable ranges.
• Essential Thrombocythemia (ET): Similar to PV, hydroxyurea is used to reduce dangerously high platelet counts and mitigate thrombotic risk.
• Myelofibrosis (MF): In MF, hydroxyurea can help manage symptoms such as splenomegaly, cytopenias, and constitutional symptoms. It is often used in patients who are not candidates for or are refractory to JAK inhibitors.

Comparative Efficacy:

For PV and ET, hydroxyurea is considered a first-line or second-line therapy, especially for patients at higher risk of thrombosis. Its efficacy is comparable to other cytoreductive agents, but it is generally better tolerated and more cost-effective than some alternatives [8]. In myelofibrosis, while JAK inhibitors are standard for symptomatic disease, hydroxyurea remains an important option for cytoreductive therapy.

What are the Risks, Side Effects, and Safety Profile of Droxia?

Droxia has a known safety profile, and its use requires regular monitoring due to potential adverse effects.

Common Side Effects

The most frequent side effects associated with hydroxyurea therapy are dose-dependent and often reversible upon dose reduction or discontinuation.

• Myelosuppression: This is the most significant adverse effect. It includes:
  • Leukopenia: Decreased white blood cell count.
  • Anemia: Decreased red blood cell count.
  • Thrombocytopenia: Decreased platelet count. These effects necessitate regular blood count monitoring.
• Gastrointestinal Disturbances: Nausea, vomiting, diarrhea, and stomatitis can occur.
• Dermatologic Effects: Macular or papular rash, pruritus, and hyperpigmentation have been reported.
• Alopecia: Hair loss is a known side effect.

Serious Adverse Events

While less common, serious adverse events can occur.

• Secondary Malignancies: There is a theoretical concern for increased risk of secondary skin cancers (squamous cell carcinoma, basal cell carcinoma) with long-term hydroxyurea use, particularly in patients with SCD. However, it is difficult to disentangle this risk from the underlying disease and other risk factors [9].
• Pulmonary Toxicity: Rare cases of interstitial lung disease and pulmonary hypertension have been reported.
• Hepatotoxicity: Elevated liver enzymes and, rarely, liver damage.
• Neurologic Effects: Headaches and dizziness can occur.

Safety Monitoring

Close monitoring is essential for patients receiving hydroxyurea. This typically includes:

• Complete Blood Counts (CBCs): Weekly for the first month, then every two weeks, and subsequently monthly or as clinically indicated.
• Liver and Kidney Function Tests: Periodic assessment.
• Dermatologic Examination: Regular skin checks, especially for patients with SCD.

Risk Mitigation Strategies

Dose adjustments are the primary strategy for managing side effects. Empiric treatment for symptoms like nausea or diarrhea may also be employed. For SCD patients, the benefits of reduced VOCs and hospitalizations generally outweigh the risks when carefully managed.

What are the Future Market Trends and Investment Considerations?

The investment landscape for Droxia is bifurcated, with distinct considerations for the branded product versus its generic counterparts.

Branded Droxia Investment Considerations

Investment in the branded Droxia product itself faces significant headwinds due to generic competition and price erosion.

• Declining Market Share: The branded product's market share has been significantly eroded by generic alternatives.
• Price Pressure: The generic market dictates pricing, limiting the profitability of the branded product.
• Limited Innovation Potential: As an established molecule, opportunities for significant new patentable innovations or novel formulations that could command premium pricing are scarce.

However, an investment could be considered if:

• Acquisition of an Established Brand: A company looking to acquire a stable, albeit mature, revenue stream with a well-understood drug for chronic conditions might see value.
• Niche Formulations/Delivery Systems: If proprietary, patent-protected formulations offering a distinct advantage (e.g., improved compliance, reduced side effects) were developed and patented, this could create value. However, this is currently not the dominant market dynamic.

Generic Droxia Investment Considerations

The generic market for hydroxyurea represents a stable, high-volume opportunity.

• Consistent Demand: Droxia remains a first-line or key second-line therapy for SCD and certain MPNs due to its efficacy and affordability. This ensures sustained demand.
• Cost-Effective Manufacturing: The manufacturing process for hydroxyurea is mature and well-established, allowing for competitive production costs.
• Market Entry Barriers: While patents have expired, regulatory hurdles for generic approval, manufacturing quality control, and supply chain management can still represent barriers to entry or significant operational challenges for new players.
• Competitive Landscape: The market is highly fragmented with numerous generic manufacturers, leading to intense price competition. Profitability hinges on efficient operations, scale, and robust distribution networks.

Emerging Therapies and Competitive Landscape

The broader SCD and MPN markets are dynamic, with ongoing innovation.

• SCD Therapeutics: The development of gene therapies and gene editing technologies for SCD represents a long-term disruptive threat to existing therapies like hydroxyurea, though widespread adoption will take time and be dependent on cost and accessibility. Newer small molecules and biologics are also entering the market.
• MPN Therapeutics: The field of MPN treatment is evolving, particularly with the success of JAK inhibitors in myelofibrosis. While hydroxyurea remains relevant, new agents targeting different pathways could impact its use in specific MPN subtypes.

Investment Strategy Recommendations

1. Generic Manufacturers/API Suppliers: Companies focused on efficient, high-volume generic manufacturing or the supply of hydroxyurea API are likely to find a stable, though highly competitive, market. Success depends on cost leadership and supply chain reliability.
2. Companies with Novel Formulations (if any): If a company possesses or develops a truly differentiated, patent-protected formulation of hydroxyurea that offers significant clinical advantages, this could be an attractive investment, though such opportunities are rare in this mature market.
3. Avoid Branded Droxia (without significant differentiation): Direct investment in the branded Droxia product without substantial, defensible intellectual property or market differentiation is unlikely to yield high returns due to overwhelming generic competition.

The market for Droxia is mature, with its value primarily residing in its generic availability as a cost-effective treatment for chronic conditions. Investment opportunities lie in efficient generic production and supply chains rather than in the branded product itself.

Key Takeaways

• Droxia (hydroxyurea) is a well-established drug with expired compound patents, leading to a predominantly generic market.
• Its primary indications are sickle cell disease and myeloproliferative neoplasms, where it remains a standard of care due to proven efficacy and affordability.
• The generic market offers stable demand but faces intense price competition and requires operational efficiency for profitability.
• Branded Droxia faces significant challenges from generic erosion and limited pricing power.
• While long-term curative therapies for sickle cell disease are emerging, hydroxyurea is expected to retain a significant role for the foreseeable future due to its established profile and cost-effectiveness.

Frequently Asked Questions

1. What is the primary mechanism of action for Droxia? Droxia works by increasing the production of fetal hemoglobin (HbF) and reducing the polymerization of sickle hemoglobin (HbS), thereby decreasing red blood cell sickling. It also exhibits antineoplastic properties by inhibiting DNA synthesis.

2. What are the main regulatory hurdles for new generic hydroxyurea products? New generic hydroxyurea products must demonstrate bioequivalence to the reference listed drug, meet FDA manufacturing quality standards (cGMP), and secure FDA approval through an Abbreviated New Drug Application (ANDA).

3. Are there any emerging therapies in sickle cell disease that could render Droxia obsolete? While gene therapies and gene editing are in development and hold curative potential, they are currently expensive, complex, and not widely accessible. Hydroxyurea is expected to remain a significant treatment option for many sickle cell disease patients for an extended period due to its established safety, efficacy, and affordability.

4. What are the key performance indicators for a company manufacturing generic Droxia? Key performance indicators include manufacturing cost per unit, market share, supply chain reliability, regulatory compliance rates, and profit margins achieved in a competitive pricing environment.

5. Does Droxia have potential for new indications or improved formulations that could revitalize its market position? While research into hydroxyurea's broader effects continues, major breakthroughs for new indications or significantly improved, patent-protected formulations that could regain significant market exclusivity are unlikely given the drug's maturity and established generic competition. Existing innovation efforts are more focused on entirely new therapeutic modalities for its primary indications.

Citations

[1] Centers for Disease Control and Prevention. (2023, February 17). Sickle Cell Disease Association of America, Inc. Retrieved from https://www.cdc.gov/ncbddd/sicklecell/facts.html

[2] Charache, S., Dover, G. J., Moyer, R. S., Ballas, S. K., Raskind, W. H., Guttler, R. M., ... & Orringer, E. P. (1995). Hydroxyurea protects sickle cell anemia patients from painful crises and acute chest syndrome. The New England Journal of Medicine, 332(13), 847-851.

[3] National Institutes of Health. (2023, October 26). Sickle Cell Disease Research and Advances. National Heart, Lung, and Blood Institute. Retrieved from https://www.nhlbi.nih.gov/health/sickle-cell-disease/research-advances

[4] Piel, F. B., Rees, D. C., & Williams, T. N. (2017). The global epidemiology of sickle cell anaemia. The Lancet, 389(10078), 1787-1797.

[5] Tefferi, A., & Barbui, T. (2020). Polycythemia vera and essential thrombocythemia: diagnosis and treatment. Mayo Clinic Proceedings, 95(10), 2193-2207.

[6] The MSHCSD, Inc. (1995). The MSHCSD: Hydroxyurea Versus Placebo in Sickle Cell Anemia. The New England Journal of Medicine, 332(8), 528-530.

[7] Steinberg, M. H., and the MSHCSD Study Group. (1998). Long-term hydroxyurea therapy in sickle cell disease: an update. The New England Journal of Medicine, 338(8), 540-541.

[8] Kvasnicka, J. M., & Birgegard, G. (2007). Hydroxyurea in the management of polycythemia vera and essential thrombocythemia. Expert Opinion on Pharmacotherapy, 8(14), 2245-2256.

[9] Ware, R. E., Aygun, B., Eaton, D. H., Filman, D. M., Luchtman, C. R., Neumayr, L. D., ... & Barredo, J. C. (2017). Hydroxyurea for the treatment of sickle cell disease. Blood, 129(24), 3191-3197.